Ugo De Giorgi
机构: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS Meldola ITALY
每年引用次数
引用次数
引用: 25,585
H-指数: 78
I10-指数 : 335
出版物: 912
CYP17A1 polymorphisms and clinical outcome of patients with metastatic castration-resistant prostate cancer treated with abiraterone
De Giorgi , Ugo Federico Francesco
Alma Mater Studiorum - Università di Bologna
2014
P4-07-10: Circulating Tumor Cells in Newly Diagnosed Inflammatory Breast Cancer.
M Mego , A Giordano , Giorgi U De , L Hsu
Cancer Research 71
2011
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
V Conteduca , G Gurioli , M Del Re , G Schepisi
Prostate Cancer and Prostatic Diseases 24 ( 2) 524 -531
27
2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Vanda Salutari , Giovanni Scambia , Saverio Cinieri , Sandro Pignata
Lancet Oncology 22 ( 2) 267 -276
57
2021
First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party.
G Rosti , , U De Giorgi , H Wandt
Bone Marrow Transplantation 34 ( 12) 1033 -1037
22
2004
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II–IIIA breast cancer
U De Giorgi , G Rosti , A Zaniboni , M Ballardini
Bone Marrow Transplantation 32 ( 3) 251 -255
5
2003
Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.
P Pedrazzoli , , P Ferrante , A Kulekci
Bone Marrow Transplantation 32 ( 5) 489 -494
45
2003
Sexual functions after high-dose chemotherapy in survivors of germ cell tumors.
M Monti , G Rosti , U De Giorgi , G Cavallari
Bone Marrow Transplantation 32 ( 9) 933 -939
7
2003
Long-term follow-up of patients with poor prognosis germ cell tumor treated with early high-dose chemotherapy with hematopoietic progenitor cell support: a single-center experience
U De Giorgi , G Rosti , G Papiani , M Marangolo
Bone Marrow Transplantation 33 ( 6) 639 -643
3
2004
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization
B Kopf , U De Giorgi , B Vertogen , G Monti
Bone Marrow Transplantation 38 ( 6) 407 -412
37
2006
Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
U De Giorgi , G Rosti , G Ciucci , B Kopf
Bone Marrow Transplantation 40 ( 8) 735 -739
2007
High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party.
U De Giorgi , D Blaise , A Lange , P Viens
Bone Marrow Transplantation 40 ( 11) 1045 -1048
2007
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients
M Mego , U De Giorgi , K Broglio , S Dawood
British Journal of Cancer 101 ( 11) 1813 -1816
39
2009
Peripheral blood progenitor cell (PBPC) mobilization in heavily pretreated patients with germ cell tumors: a report of 34 cases.
C Dazzi , A Cariello , G Rosti , G Monti
Bone Marrow Transplantation 23 ( 6) 529 -532
16
1999
Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer
M Mego , H Gao , EN Cohen , S Anfossi
Journal of Cancer 7 ( 9) 1095 -1104
39
2016
Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours
U De Giorgi , , G Rosti , S Slavin
British Journal of Cancer 93 ( 4) 412 -417
55
2005
Hyperthermia and hypoxia: new developments in anticancer chemotherapy
N Zaffaroni , G Fiorentini , U De Giorgi
Ejso 27 ( 4) 340 -342
34
2001
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
S Salvi , V Casadio , V Conteduca , S L Burgio
British Journal of Cancer 112 ( 10) 1717 -1724
88
2015
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
M Santoni , U De Giorgi , R Iacovelli , A Conti
British Journal of Cancer 109 ( 7) 1755 -1759
65
2013
Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients.
M Celli , U De Giorgi , P Caroli , V Di Iorio
European Journal of Nuclear Medicine and Molecular Imaging 48 ( 1) 87 -94
2
2021